Fear of Cancer Recurrence Questionnaire (CMRC)

Abstract

The Cuestionario de Miedo a la Recurrencia del Cáncer (CMRC), translated as the Fear of Cancer Recurrence Questionnaire, is an 8-item self-report psychometric instrument developed to evaluate the severity, intrusive nature, and functional impact of fear of cancer recurrence (FCR) among Spanish-speaking cancer survivors. Formulated by Celia Ibáñez del Prado and colleagues at the Universidad Complutense de Madrid and the Hospital Universitario Clínico San Carlos, the CMRC was engineered to remediate the historical lack of brief, rigorously validated FCR screening tools specifically adapted to Spanish clinical oncology contexts. The instrument was constructed from an initial conceptual pool of 22 candidate items extracted through systematic literature synthesis of international FCR inventories. Following quantitative expert content validation, 12 items exhibiting inadequate content representation were eliminated. The intermediate 10-item version was psychometrically administered to a clinical sample of gynecological cancer survivors in Spain, after which item-analysis demonstrated that the excision of two redundant items optimized the scale’s internal consistency and parsimony, producing the definitive 8-item unidimensional architecture.

Psychometrically, the CMRC exhibits robust reliability and validity parameters. Items are rated on a 5-point Likert-type response scale ranging from 0 (“No en absoluto / Not at all”) to 4 (“Totalmente de acuerdo / Totally agree”), yielding a global score ranging from 0 to 32. Content validity was quantitatively confirmed by expert panel evaluation, with all retained items demonstrating Aiken’s V coefficients exceeding 0.76. Internal consistency is high, evidenced by a Cronbach’s alpha coefficient of α = 0.851. Predictive and convergent validity analyses revealed statistically significant positive correlations with state and trait anxiety measures on the Hospital Anxiety and Depression Scale (HADS) and an exceptionally strong association with the single-item Escala General del Miedo a la Recurrencia del Cáncer (EGMRC; r = 0.841, p < 0.01). Furthermore, the CMRC demonstrated selective criterion validity by inversely correlating with the emotional functioning domain of health-related quality of life (r = −0.313, p = 0.05), while displaying discriminant divergence from depressive symptomatology and generic physical symptom burdens. The instrument provides psycho-oncologists with an efficient, reliable, and clinically sensitive assessment tool for routine survivor follow-up.

Keywords

Fear of Cancer Recurrence, CMRC, Psycho-Oncology, Cancer Survivorship, Gynecological Oncology, Psychometrics, Health-Related Quality of Life, Illness Cognition, Anxiety Assessment, Oncology Screening

Authors

The Cuestionario de Miedo a la Recurrencia del Cáncer (CMRC) was developed and validated by a multidisciplinary team of psycho-oncologists, clinical psychologists, and medical oncologists based in Madrid, Spain:

• Celia Ibáñez del Prado, Ph.D. – Facultad de Psicología, Universidad Complutense de Madrid (UCM), Madrid, Spain. Email: [email protected] (Corresponding Author).
• Volha Zontava Aleksandrovna – Facultad de Psicología, Universidad Complutense de Madrid (UCM), Madrid, Spain. Email: [email protected].
• Juan Antonio Cruzado, Ph.D. – Departamento de Personalidad, Evaluación y Tratamiento Psicológico, Facultad de Psicología, Universidad Complutense de Madrid (UCM), Madrid, Spain. Email: [email protected].
• Gloria Marquina Ospina, M.D. – Servicio de Oncología Médica, Hospital Universitario Clínico San Carlos, Madrid, Spain. Email: [email protected].
• Javier García Santos, M.D. – Instituto de Salud de la Mujer, Hospital Universitario Clínico San Carlos, Madrid, Spain. Email: [email protected].
• Inés Rodríguez Nodal – Facultad de Psicología, Universidad Complutense de Madrid (UCM), Madrid, Spain. Email: [email protected].
• Mónica Bellón del Amo, M.D. – Instituto de Salud de la Mujer, Hospital Universitario Clínico San Carlos, Madrid, Spain. Email: [email protected].
• Aránzazu Manzano Fernández, M.D. – Servicio de Oncología Médica, Hospital Universitario Clínico San Carlos, Madrid, Spain.
• Antonio Casado Herráez, M.D., Ph.D. – Servicio de Oncología Médica, Hospital Universitario Clínico San Carlos, Madrid, Spain. Email: [email protected].

Institutional Correspondence Address:
Dr. Celia Ibáñez del Prado, Facultad de Psicología, Universidad Complutense de Madrid, Campus de Somosaguas, 28223 Pozuelo de Alarcón, Madrid, Spain.

Purpose

Fear of cancer recurrence (FCR) is defined internationally as the fear, worry, or concern relating to the possibility that cancer will return or progress in the primary site or in metastatic locations (Lebel et al., 2016). Across oncology populations, FCR ranks consistently as one of the most prevalent, persistent, and distressing unmet supportive care needs reported by survivors following curative-intent primary treatment. While mild levels of apprehension represent an understandable, normative psychological adaptation to a life-threatening medical illness, clinical or pathological FCR is characterized by pervasive intrusive ruminations, cognitive preoccupation, debilitating affect, maladaptive coping mechanisms (such as hypervigilant body-checking or healthcare avoidance), and marked disruption of everyday functional domains.

The primary purpose of the Cuestionario de Miedo a la Recurrencia del Cáncer (CMRC) is to provide a brief, psychometrically sound, self-administered measurement tool engineered specifically to assess the severity, behavioral manifestations, and functional interference of FCR in Spanish-speaking cancer survivors. Prior to its construction, the assessment of FCR across Spain and Latin America relied heavily on direct translations of extensive English-language batteries, such as the 42-item Fear of Cancer Recurrence Inventory (FCRI) or the 22-item Concerns About Recurrence Scale (CARS). Although comprehensive, these expansive instruments present substantial respondent burden in fast-paced oncological consultation rooms, acute chemotherapy infusion suites, and routine surveillance visits.

The CMRC resolves this methodological dilemma by concentrating on core indicators of clinical FCR into an 8-item self-report questionnaire. Its clinical and research purposes include:

• First-Line Clinical Screening: Rapidly identifying cancer survivors who experience clinically elevated, maladaptive fear that requires formal psychological triage and targeted psycho-oncological care.
• Intervention Monitoring and Outcome Evaluation: Serving as an objective, sensitive pre- and post-test measurement index for randomized controlled trials (RCTs) evaluating cognitive-behavioral therapy (CBT), acceptance and commitment therapy (ACT), and mindfulness-based cancer recovery interventions.
• Epidemiological and Longitudinal Survivorship Studies: Facilitating longitudinal tracking of illness representations, trajectories of worry, and psychological morbidity across different survival milestones (e.g., transition from active therapy to discharge, seasonal follow-up visits, or multi-year disease-free status).
• Differentiating Normal vs. Dysfunctional Coping: Distinguishing benign, situational concerns triggered by routine oncology surveillance scans (commonly termed “scanxiety”) from entrenched cognitive avoidance, perceived social alienation, and inability to formulate future life commitments.

Psychological Construct

The psychological construct evaluated by the CMRC is multidimensional in theoretical scope yet integrated into a unified severity continuum capturing the psychological impact of cancer-related recurrence fears. The construct encompasses distinct cognitive, emotional, behavioral, and functional domains identified across psycho-oncology literature:

1. Affective Distress and Subjective Worry

At its baseline, FCR involves an emotional state of distress characterized by persistent anticipatory anxiety, dread, and subjective preoccupation regarding oncological relapse. In the CMRC, this affective dimension is measured by direct appraisals of anxiety intensity and the subjective perception that recurrence worry represents an unmanageable burden (e.g., Item 1: “Estoy preocupado/a o ansioso/a por la posibilidad de volver a tener cáncer”; Item 2: “La preocupación sobre la vuelta del cáncer supone un gran problema para mí”). This captures not merely the presence of a cognitive thought about cancer, but the negative valence and subjective suffering attached to that cognition.

2. Cognitive Intrusion and Thought Suppression

Pathological recurrence fears are distinguished from normative vigilance by their intrusive, recurrent, and uncontrollable nature. Survivors experiencing high FCR report involuntary thoughts that disrupt daytime focus and evening rest. In response to these intrusive cognitions, patients frequently employ metacognitive suppression strategies (e.g., Item 6: “Cuando me asaltan los pensamientos sobre la vuelta del cáncer trato de evitarlos”). Paradoxically, as predicted by cognitive psychology models of thought suppression, active efforts to block or eliminate cancer thoughts often amplify their frequency, creating a self-perpetuating cycle of cognitive intrusion and distress.

3. Behavioral Avoidance and Environmental Triggers

A critical behavioral marker of clinically significant FCR is behavioral avoidance. Patients alter their daily routines to avoid external reminders of malignancy, such as media stories about cancer, health-related conversations, or physical places associated with prior treatments (e.g., Item 8: “Evito situaciones o cosas que me hacen pensar en la posibilidad de que el cáncer reaparezca”). Furthermore, medical follow-up consultations and scheduled diagnostic imaging serve as potent conditioned environmental triggers that evoke acute spikes in fear (e.g., Item 5: “Las revisiones médicas me hacen sentir miedo por la posible vuelta del cáncer”).

4. Functional Interference and Future Disruption

The ultimate diagnostic hallmark separating non-clinical worry from severe psychological disturbance is functional impairment. The CMRC explicitly gauges the degree to which intrusive recurrence thoughts paralyze the survivor’s hedonistic capacity and existential orientation. This includes an inability to enjoy day-to-day life activities (e.g., Item 3: “Pensar en la posibilidad de que el cáncer vuelva me impide disfrutar de las cosas como lo hacía antes de la enfermedad”) and a pervasive hesitancy or inability to establish future occupational, financial, or interpersonal plans (e.g., Item 7: “Mi temor a que el cáncer vuelva me dificulta hacer planes de futuro”).

5. Perceived Social Disconnect

Finally, the construct incorporates the interpersonal perception of one’s worry. Survivors struggling with elevated FCR often perceive that their immediate family members, partners, or friends consider their preoccupation excessive or irrational (e.g., Item 4: “Las personas cercanas a mí consideran que me preocupo excesivamente porque vuelva el cáncer”). This perception of excessive worry can generate interpersonal friction, communicative withdrawal, and profound feelings of loneliness, amplifying the psychological burden of survivorship.

Theoretical Framework

The conceptualization and operationalization of the CMRC are deeply anchored in two prominent psychological paradigms: Howard Leventhal’s Common-Sense Model of Self-Regulation (CSM) and contemporary Cognitive-Behavioral formulations of health anxiety and fear of recurrence (Fardell et al., 2016; Lee-Jones et al., 1997).

Leventhal’s Common-Sense Model of Self-Regulation (CSM)

The CSM posits that when individuals encounter health threats, they construct parallel cognitive and emotional mental representations of the illness to guide their coping behaviors and adaptive responses. These representations comprise five core cognitive dimensions: identity (symptoms and labels), timeline (acute, chronic, or cyclical), consequences (anticipated physical, social, and economic impacts), cause (etiological attributions), and controllability/cure (beliefs regarding the efficacy of medical treatments and self-care).

In the context of cancer survivorship, acute treatment completion typically eliminates somatic evidence of active disease; however, internal somatic sensations (such as benign aches, scar tenderness, fatigue, or minor infections) frequently trigger misattributions of disease relapse. When survivors operate under a chronic or recurring timeline representation paired with catastrophic beliefs regarding consequences, mundane somatic sensations are misinterpreted as lethal recurrences. The CMRC directly operationalizes the cognitive and emotional pathways of the CSM by assessing how these catastrophic illness representations overwhelm the patient’s emotional regulatory systems, leading to avoidance-driven coping and perceived loss of control over the personal timeline.

Cognitive-Behavioral and Metacognitive Models of FCR

Expanding beyond the CSM, the Blended Cognitive-Behavioral Model of FCR (Fardell et al., 2016) integrates cognitive processing theories with metacognitive models of generalized anxiety disorder. This framework identifies several recursive feedback loops that sustain dysfunctional FCR:

• Metacognitive Beliefs: Survivors hold both positive metacognitive beliefs (e.g., “Worrying about cancer keeps me safe and ensures I catch a recurrence early”) and negative metacognitive beliefs (e.g., “My recurrence worries are uncontrollable and will drive me insane”).
• Cognitive Attentional Syndrome (CAS): Activation of the CAS leads to hypervigilant body-monitoring, scanning for somatic abnormalities, and sustained rumination.
• Maladaptive Coping Behaviors: In an attempt to reduce the acute distress provoked by the CAS, patients engage in behavioral avoidance (refusing to attend clinics or read health information) or cognitive suppression. Because avoidance and suppression prevent emotional processing and reality-testing, the threat beliefs remain uncalibrated and persistently elevated.

The CMRC items mirror this cognitive-behavioral architecture: somatic reminders and clinical follow-ups act as external triggers (Item 5), eliciting cognitive intrusion and suppression (Item 6), which then translate into maladaptive behavioral avoidance (Item 8) and generalized disruption of functional life engagement (Items 3 and 7).

Validity

The psychometric validation of the CMRC conducted by del Prado et al. (2023) established robust evidence supporting its content, predictive, convergent, and discriminant validity across clinical survivorship cohorts.

Content Validity and Item Development

The instrument underwent a rigorous multi-stage development methodology. The authors initiated the process with an initial pool of 22 candidate items derived from a comprehensive review of existing international FCR psychometric instruments. To ensure content validity, an expert panel consisting of clinical psychologists, psycho-oncologists, and medical oncologists evaluated the items for clinical relevance, clarity, semantic precision, and structural representativeness within the Spanish oncological population.

Quantitatively, expert evaluations were analyzed using Aiken’s V coefficient of content validity. Items demonstrating inadequate consensus or Aiken’s V values below established thresholds were discarded, leading to the immediate elimination of 12 items. For all retained items, Aiken’s V coefficients exceeded 0.76, confirming high content representativeness and clinical fidelity. Subsequent pilot administration of the intermediate 10-item instrument to gynecological cancer survivors revealed that removing two further psychometrically redundant items heightened internal consistency and minimized assessment burden, leaving the final 8-item version.

Predictive and Convergent Validity

The predictive and convergent validity of the CMRC was evaluated by correlating total scores against well-validated external criteria:

• Single-Item Concurrent Criterion: The CMRC displayed a powerful, statistically significant positive correlation with the single-item Escala General del Miedo a la Recurrencia del Cáncer (EGMRC; del Prado et al., 2023), exhibiting a Pearson correlation of r = 0.841 (p < 0.01). This robust association confirms that the 8-item composite captures the core variance of the overarching construct of recurrence fear.
• Anxiety Symptomatology: Significant positive correlations were documented between the CMRC and anxiety symptoms measured via the Hospital Anxiety and Depression Scale – Anxiety Subscale (HADS-A; Zigmond & Snaith, 1983). Survivors with elevated CMRC scores reported markedly higher general affective anxiety.
• Quality of Life Associations: When correlated with the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), the CMRC demonstrated a statistically significant negative correlation specifically with the Emotional Functioning subscale (r = −0.313, p = 0.05). Higher fear of recurrence directly tracked decrements in emotional well-being.

Discriminant Validity

Importantly, the CMRC exhibited notable discriminant specificity. Total scores did not demonstrate statistically significant correlations with the HADS Depression Subscale (HADS-D), substantiating the theoretical tenet that FCR is conceptually distinct from clinical depression. While depression in cancer survivorship is characterized by anhedonia, passivity, psychomotor slowing, and helplessness regarding past losses, FCR is fundamentally an anticipatory, hyperarousal-driven anxiety construct focused on impending somatic threats. Additionally, CMRC scores did not significantly correlate with global generic physical symptom scales of the EORTC QLQ-C30, verifying that the scale measures psychological and cognitive processing rather than mere physical disease burden.

Reliability

The internal consistency and measurement precision of the CMRC have been confirmed through classical test theory analyses:

• Cronbach’s Alpha (α): The definitive 8-item version demonstrated high internal consistency, yielding an overall Cronbach’s alpha coefficient of α = 0.851. This value resides comfortably within the optimal psychometric bracket (≥ 0.80 and ≤ 0.90), reflecting excellent construct homogeneity without redundant item tautology.
• Item-Total Correlations: During scale refinement, corrected item-total correlations across the retained 8 items were robust and uniformly positive. The strategic removal of the two lowest-performing items from the 10-item draft directly enhanced overall scale reliability, ensuring that every individual statement significantly contributes to the measurement of the target construct.
• Standard Error of Measurement (SEM): The elevated internal consistency (α = 0.851) minimizes measurement error variance, providing clinicians and researchers with stable, reproducible score estimates during individual clinical evaluations and group-level clinical trials.

Factor Analysis

In the primary empirical validation study by del Prado et al. (2023), the initial development framework and item reduction procedures favored a parsimonious, unidimensional measurement model designed for rapid clinical deployment. Factor-analytic and item reduction evaluations revealed that the 8 retained items converge on a single dominant latent factor representing Global Fear of Cancer Recurrence Severity.

While expansive legacy measures (such as the 42-item FCRI) feature multi-factor models parsing FCR into triggers, severity, psychological distress, coping strategies, functional impairments, and insight, the CMRC captures the shared core variance across these subdomains within a streamlined, one-factor solution. The 8 items load consistently onto this unified dimension, capturing the spectrum from mild intrusive thoughts to profound functional paralysis. del Prado and colleagues noted that while exploratory factor analytic metrics from the pilot sample supported a unidimensional construct, future large-scale confirmatory factor analyses (CFA) across diverse oncological populations (e.g., breast, colorectal, prostate, and hematologic malignancies) are recommended to confirm structural invariance across cancer types and genders.

Instrument / Measurement Tool

The Cuestionario de Miedo a la Recurrencia del Cáncer (CMRC) is an objective, standardized psychometric rating scale designed for individual or group administration in clinical oncology, psychological practice, and research environments.

• Instrument Name: Cuestionario de Miedo a la Recurrencia del Cáncer (CMRC)
• English Translation: Fear of Cancer Recurrence Questionnaire (CMRC)
• Test Type: Original self-report rating scale
• Administration Format: Paper-and-pencil or digital/electronic survey administration
• Administration Time: Approximately 2 to 3 minutes
• Target Population: Adult cancer survivors (≥ 18 years of age) who have completed curative-intent primary oncological treatment. Validated primarily in gynecological cancer survivors across adult, middle-aged, and elderly cohorts.
• Language Available: Spanish (original validated language)
• Number of Items: 8 items
• Response Format: 5-point Likert-type scale scored as:
  • 0 = No en absoluto (Not at all)
  • 1 = Poco (A little)
  • 2 = Medianamente (Moderately)
  • 3 = Mucho (A lot)
  • 4 = Totalmente de acuerdo (Totally agree)
• Scoring and Quantification:
  • All 8 items are positively keyed. There are no reverse-scored items.
  • The global score is calculated by summing the numerical ratings across all 8 items:
    
    Total CMRC Score = ∑ (Item 1 to Item 8)
  • Score Range: Scores range from a minimum of 0 to a maximum of 32.
  • Clinical Interpretation: Higher total scores indicate greater severity of fear of cancer recurrence, more frequent intrusive thoughts, greater reliance on cognitive-behavioral avoidance, and heightened functional impairment.

Permissions & Fee and Test Year

• Publication Year: 2023
• Copyright & Intellectual Property: © 2023 del Prado, Aleksandrovna, Cruzado, Marquina Ospina, García Santos, Rodríguez Nodal, Bellón del Amo, Manzano Fernández, and Casado Herráez.
• Licensing and Open Access: The instrument is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
• Usage Permissions: The CMRC may be reproduced, distributed, and utilized freely for academic, non-commercial clinical, and scientific research purposes without prior written authorization from the authors, provided that appropriate attribution is cited.
• Fee: Free of charge (No fee required).
• Commercial Exploitation: Commercial re-licensing or integration into proprietary fee-based software platforms requires formal permission from the original copyright holders.

References

• del Prado, C. I., Aleksandrovna, V. Z., Cruzado, J. A., Ospina, G. M., Santos, J. G., Nodal, I. R., del Amo, M. B., Fernández, A. M., & Herráez, A. C. (2023). Evaluación del miedo a la recurrencia del cáncer en español: El Cuestionario de Miedo a la Recurrencia del Cáncer y Escala General del Miedo a la Recurrencia del Cáncer: un estudio piloto [Assessment of fear of cancer recurrence in Spanish: Fear of Recurrence Questionnaire and the General Scale of Fear of Cancer Recurrence: A pilot study]. Psicooncología, 20(1), 155–173. https://doi.org/10.1007/s10549-023-07085-0
• Fardell, J. E., Thewes, B., Turner, J., Gilchrist, J., Sharpe, M., Smith, A. B., Girgis, A., & Butow, P. (2016). Fear of cancer recurrence: A review of the theoretical models and operational definitions. Psycho-Oncology, 25(9), 1018–1030. https://doi.org/10.1002/pon.4162
• Lebel, S., Ozakinci, G., Humphris, G., Mutsaers, B., Thewes, B., Prins, J., Dinkel, A., & Butow, P. (2016). From normal response to clinical problem: Definition and clinical features of fear of cancer recurrence. Journal of Cancer Survivorship, 10(6), 1103–1107. https://doi.org/10.1007/s11764-016-0578-3
• Lee-Jones, C., Humphris, G., Dixon, R., & Hatcher, M. B. (1997). Fear of cancer recurrence—A literature review and proposed cognitive formulation to explain executive functioning. Psycho-Oncology, 6(2), 95–105. https://doi.org/10.1007/s10865-016-9782-2
• Simard, S., & Savard, J. (2009). Fear of Cancer Recurrence Inventory: Development and initial validation of a multidimensional measure. Journal of Cancer Survivorship, 3(4), 241–251. https://doi.org/10.1007/s11764-009-0097-x
• Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 67(6), 361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x

Items of the Scale